Organon achieves milestone in Asenapine development collaboration
The achievement of the milestone, of which no further specifics were disclosed, reconfirms the commitment of both companies to fully explore the clinical potential.
Asenapine is a novel psychotherapeutic investigational drug being developed for the treatment of psychotic and mood disorders. It has a unique neuropharmacological receptor signature that distinguishes it from current antipsychotics, antidepressants and mood stabilizers. Early clinical results indicate that asenapine will restore balance to a patient's life through superior relief of negative symptoms and strong control of positive symptoms in schizophrenia. Reduction of manic symptoms in bipolar disorder are also being evaluated. Current knowledge suggests asenapine to have an excellent safety profile and to be well tolerated. The phase III clinical development program is expected to be finalized by the end of 2006, with an NDA submission foreseen early 2007.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.